Tuesday 28 August 2018

Targeting the Immune Checkpoint in Cancer: Is This a Viable Treatment Option for AML?: (OAJOM)-Lupine Publishers

Targeting the Immune Checkpoint in Cancer: Is this a Viable Treatment Option for AML? by Steven J Coles in Open Access Journal of Oncology and Medicine in Lupine Publishers

 The immune suppressive mechanisms displayed by malignant cells are considered a central process in the pathogenesis of cancer. Research in this area has gained significant momentu mover the past 20 years, with several immune checkpoints identified, including; CTLA-4, CD200/CD200R, Tim-3/Galectin-9 and PD-L1/PD-1 (Figure 1). Whilst characterising the molecular basis of leukaemia for risk stratification remains at the forefront of AML research; this must now extend to understating how the seimmune checkpoint path ways fit into the equation.








No comments:

Post a Comment

Note: only a member of this blog may post a comment.